METAvivor Translational Research Award
The METAvivor Translational Research Award funds research to advance understanding, diagnosis, and treatment of metastatic breast cancer through basic, translational, or clinical science.
This grant is no longer accepting proposals
METAvivor has archived this opportunity.
Funder: METAvivor
Due Dates: March 16, 2026 (LOI, 2026 cycle) | March 11, 2025 (LOI, 2025 cycle)
Funding Amounts: Up to $450,000 total over three years per award.
Summary: Supports established investigators conducting basic, translational, or clinical research addressing key barriers in metastatic breast cancer (MBC).
Description
The METAvivor Translational Research Award provides substantial funding to established investigators for research projects that seek to advance the understanding, diagnosis, and treatment of metastatic breast cancer (MBC). The program specifically supports discovery and early-phase basic, translational, and clinical research aimed at addressing critical problems or barriers to progress in the field. Projects that focus on mechanistic insights, novel diagnostic approaches, or new therapeutic strategies for MBC are encouraged. Research aimed at improving quality of life or mitigating side effects for people living with MBC may also be considered.
